FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, not for consumption, not medicines. Research use policy
UK only · Prepared to order · approx. 7 days + Royal Mail Tracked 24 · No international shipping
Britpep
Basket 0
ACE-031 1 mg research peptide vial View vial label (BP-ACE031-1) →
Recombinant fusion protein · Lyophilised vial

ACE-031

Cell-signalling research peptides

Soluble activin receptor type IIB–Fc fusion protein (ActRIIB-Fc), studied in TGF-β superfamily signalling research.

Areas of research interest
£75.99 ex. VAT · per vial
Available

Prepared to order · approx. 7 days + Royal Mail Tracked 24

SKU BP-ACE031-1 · per batch COA · Lyophilised powder

For laboratory research use only. Not for human or veterinary use. Not a medicine, food supplement or cosmetic. Purchasers confirm research use, age 18+ and institutional/professional status at checkout. UK delivery only.
Data pending verification. Identity data in the specification below has been compiled for pre-launch and is awaiting verification against supplier documentation and batch COAs. Highlighted fields are unconfirmed.
Note: Recombinant protein: identity, expression system, purity method and endotoxin level must be confirmed from the supplier COA. The supplier's '≥99%' purity specification needs checking for a protein product. Purity specification to be confirmed against the supplier COA.

ACE-031 overview

ACE-031 is a recombinant fusion protein made of the extracellular domain of human activin receptor type IIB linked to the Fc region of human IgG1. It is supplied as a lyophilised solid for in-vitro laboratory research.

Molecular formula
Not applicable (recombinant protein)
Molecular weight
Dimeric fusion protein, approximately 100+ kDa [TO VERIFY against supplier COA]
Purity
per batch COA
Form
Lyophilised powder
Vial sizes & prices
1 mg – £75.99 (ex. VAT)
Delivery
UK only · prepared to order (approx. 7 days) then Royal Mail Tracked 24, £5.95

ACE-031 research background

Clinical trials – mixed results

Evidence status: Findings summarised here include controlled human trials with mixed or negative results, alongside preclinical research. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.

Established research

Peer-reviewed published findings, with references
Overview & discovery history
  • ACE-031 (ramatercept) is a recombinant fusion protein, not a short peptide. It combines the extracellular domain of activin receptor type IIB (ActRIIB) with a human IgG1 Fc fragment, and acts as a ligand trap for myostatin and related TGF-β-family ligands. [1][2].
Chemical identity
Sequence
Recombinant ActRIIB extracellular domain fused to human IgG1 Fc (dimeric fusion protein). Full sequence not provided by supplier [TO VERIFY against supplier COA]
Molecular formula
Not applicable (recombinant protein)
Molecular weight
Dimeric fusion protein, approximately 100+ kDa [TO VERIFY against supplier COA]
CAS number
Not established [TO VERIFY against supplier COA]
Form
Lyophilised powder
Purity
per batch COA
Format
Lyophilised vial
Vial sizes
1 mg

Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.

Mechanisms investigated
  • Sequestration of myostatin and activins, reducing ActRIIB signalling in muscle [1].
Research areas & model types
Research areaModel typeSummary
Skeletal muscle massMouse[1]
Muscle mass and strengthNon-human primate (marmoset)[4]
Healthy postmenopausal womenHuman (Phase 1)[2]
Duchenne muscular dystrophyHuman (Phase 2 RCT)[3]
Human clinical research status
  • A Phase 2 trial in boys with Duchenne muscular dystrophy was discontinued; non-muscle adverse events contributed to the decision [3]. ACE-031 is not an approved medicine.
Safety observations reported in studies
  • The single-dose Phase 1 study reported it as generally well tolerated [2]. In the DMD trial, non-muscle adverse events contributed to stopping the study [3].
Known limitations
  • Clinical development was discontinued.
Storage & handling for laboratory use

Store at −20 °C. Protect from light.

Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.

  • Allow the sealed vial to reach room temperature before opening to limit condensation.
  • Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
  • Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.

Emerging & theoretical

Unconfirmed — hypotheses & ongoing research

These are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.

Hypotheses proposed by researchers

  • Researchers continue to propose ActRIIB-pathway inhibition as a strategy in neuromuscular research [3][4].

Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.

References

  1. Cadena SM, Tomkinson KN, Monnell TE et al.. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol (1985). 2010. PubMed 20466801 · doi:10.1152/japplphysiol.00866.2009
  2. Attie KM, Borgstein NG, Yang Y et al.. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013. PubMed 23169607 · doi:10.1002/mus.23539
  3. Campbell C, McMillan HJ, Mah JK et al.. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017. PubMed 27462804 · doi:10.1002/mus.25268
  4. Cadena SM, Bogdanovich S, Khurana TS et al.. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PLoS One. 2026. PubMed 41686840 · doi:10.1371/journal.pone.0342666

Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.

Certificates of analysis

[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]

Open the COA checker

Related research compounds

ARA-290 (Cibinetide) research peptide vial
Peptide · Lyophilised vial

ARA-290 (Cibinetide)

10 mg
£30.49View
BPC-157 research peptide vial
Peptide · Lyophilised vial

BPC-157

5 mg · 10 mg · 20 mg
From £14.49View
BPC-157 / GHK-Cu / TB-500 blend research peptide vial
Peptide blend · Lyophilised vial

BPC-157 / GHK-Cu / TB-500 blend

70 mg
£42.49View
BPC-157 / TB-500 blend research peptide vial
Peptide blend · Lyophilised vial

BPC-157 / TB-500 blend

10 mg · 20 mg
From £32.99View

Browse similar compounds: Cell-signalling research peptides or the full catalogue.